Abstract
We compared neutralizing antibody titers of convalescent samples collected before and after the emergence of novel strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), against the wild-type virus and Alpha (B.1.1.7) and Beta (B.1.351) variants. Plasma samples collected in 2020 before emergence of variants showed reduced titers against the Alpha variants, and both sets of samples demonstrated significantly reduced titers against Beta. Comparison of microneutralization titers with those obtained with pseudotype and hemagglutination tests showed a good correlation between their titers and effects of strain variation, supporting the use of these simpler assays for assessing the potency of convalescent plasma against currently circulating and emerging strains of SARS-CoV-2.
| Original language | English |
|---|---|
| Pages (from-to) | 971-976 |
| Number of pages | 6 |
| Journal | Journal of Infectious Diseases |
| Volume | 225 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 15 Mar 2022 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Keywords
- SARS-CoV-2
- convalescent plasma
- hemagglutination test
- live virus neutralizing antibody assay
- neutralizing antibodies
- pseudotype
- variants
